{
    "organizations": [],
    "uuid": "0caea77148dd7476f36f1cf57fc052ec085840f8",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-rexahn-pharmaceuticals-collaborate/brief-rexahn-pharmaceuticals-collaborates-with-zhejiang-haichang-biotechnology-idUSFWN1PY124",
    "ord_in_thread": 0,
    "title": "BRIEF-Rexahn Pharmaceuticals Collaborates With Zhejiang Haichang Biotechnology",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 8 (Reuters) - Rexahn Pharmaceuticals Inc:\n* REXAHN PHARMACEUTICALS ANNOUNCES COLLABORATION WITH ZHEJIANG HAICHANG BIOTECHNOLOGY CO., LTD. FOR THE DEVELOPMENT OF RX-0201 (ARCHEXIN®) FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA\n* REXAHN PHARMACEUTICALS INC - IN CONNECTION WITH AGREEMENT WITH HAICHANG, REXAHN PLANS TO DISCONTINUE INTERNALLY FUNDED PROGRAMS OF ARCHEXIN\n* REXAHN PHARMACEUTICALS INC - REXAHN WILL ALSO CEASE ENROLLMENT IN CURRENT PHASE IIA CLINICAL STUDY OF ARCHEXIN IN METASTATIC RENAL CELL CARCINOMA\n* REXAHN PHARMACEUTICALS - ‍UNDER TERMS OF DEAL, HAICHANG WILL DEVELOP A NANO-LIPOSOMAL FORMULATION OF RX-0201 USING ITS PROPRIETARY QTSOME TECHNOLOGY​\n* REXAHN - PARTIES TO SHARE DOWNSTREAM LICENSING FEES, ROYALTIES PAID RELATED TO DEVELOPMENT,COMMERCIALIZATION OF NANO-LIPOSOMAL FORMULATION OF RX-0201 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-08T21:17:00.000+02:00",
    "crawled": "2018-02-09T16:47:18.004+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "rexahn",
        "pharmaceutical",
        "inc",
        "rexahn",
        "pharmaceutical",
        "announces",
        "collaboration",
        "zhejiang",
        "haichang",
        "biotechnology",
        "development",
        "treatment",
        "hepatocellular",
        "carcinoma",
        "rexahn",
        "pharmaceutical",
        "inc",
        "connection",
        "agreement",
        "haichang",
        "rexahn",
        "plan",
        "discontinue",
        "internally",
        "funded",
        "program",
        "archexin",
        "rexahn",
        "pharmaceutical",
        "inc",
        "rexahn",
        "also",
        "cease",
        "enrollment",
        "current",
        "phase",
        "iia",
        "clinical",
        "study",
        "archexin",
        "metastatic",
        "renal",
        "cell",
        "carcinoma",
        "rexahn",
        "pharmaceutical",
        "term",
        "deal",
        "haichang",
        "develop",
        "formulation",
        "using",
        "proprietary",
        "qtsome",
        "rexahn",
        "party",
        "share",
        "downstream",
        "licensing",
        "fee",
        "royalty",
        "paid",
        "related",
        "development",
        "commercialization",
        "formulation",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}